Prevention of Chest Pain in Chemo-treated Cancer Patients
Launched by VEJLE HOSPITAL · Mar 26, 2018
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically verified cancer
- • First-time treatment with 5-FU/Capecitabine
- • Expected remaining lifetime \> 6 months
- • Informed consent
- Exclusion Criteria:
- • Known ischemic heart disease
- • Ischemia-suspicious symptoms prior to 5-FU treatment
- • Ischemia-suspicious ECG-changes prior to 5-FU treatment
About Vejle Hospital
Vejle Hospital is a leading healthcare institution in Denmark, dedicated to advancing medical research and enhancing patient care through innovative clinical trials. With a focus on multidisciplinary collaboration, Vejle Hospital leverages its state-of-the-art facilities and experienced research teams to conduct rigorous studies across various therapeutic areas. Committed to ethical standards and patient safety, the hospital aims to contribute valuable insights to the medical community, ultimately improving treatment outcomes and healthcare practices. Through its clinical trial initiatives, Vejle Hospital strives to foster a culture of scientific excellence and drive advancements in health and medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vejle, , Denmark
Patients applied
Trial Officials
Vibeke B Hansen, MD, PhD
Principal Investigator
Vejle Hospital
Lars H Jensen, MD, PhD
Study Chair
Department of Oncology, Vejle Hospital, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials